QS-21 putative receptor

The QS-21 putative receptor refers to the hypothesized molecular target(s) through which the saponin adjuvant QS-21 exerts its potent immunostimulatory effects. While a single definitive receptor has not been universally confirmed, two primary candidates are frequently cited: the T-cell surface protein CD2 (Cluster of Differentiation 2) and the dendritic cell lectin receptor DC-SIGN (Dendritic Cell-Specific Intercellular adhesion molecule-3-Grabbing Non-integrin). The interaction with CD2 is thought to involve the formation of a Schiff base between the adjuvant's aldehyde group and the receptor's amino groups, providing a co-stimulatory signal for T-cell activation. Alternatively, QS-21 may engage DC-SIGN through its oligosaccharide moiety to facilitate antigen uptake. Beyond surface receptors, QS-21 is known to target the lysosomal membrane, causing destabilization that allows antigens to enter the cytosol for cross-presentation and activates the NLRP3 inflammasome. This multifaceted mechanism makes QS-21 a critical component in modern vaccines for shingles, malaria, and COVID-19, as it effectively bridges innate and adaptive immunity. Recent research initiatives, such as the QS21-Mech project, utilize photoaffinity probes to definitively identify these interacting partners and elucidate the precise molecular pathways involved.

Other names

CD2DC-SIGNSaponin receptorCluster of differentiation 2Dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrinCD209

Adjuvant activity via T-cell co-stimulation, lysosomal destabilization, and NLRP3 inflammasome activation